Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H11N3O4 |
Molecular Weight | 273.2441 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
InChI
InChIKey=UVSMNLNDYGZFPF-UHFFFAOYSA-N
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
Molecular Formula | C13H11N3O4 |
Molecular Weight | 273.2441 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=10386948; https://www.ncbi.nlm.nih.gov/pubmed/?term=19009291;
http://www.ncbi.nlm.nih.gov/pubmed/?term=12649301;
https://www.ncbi.nlm.nih.gov/pubmed/?term=16115943
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=10386948; https://www.ncbi.nlm.nih.gov/pubmed/?term=19009291;
http://www.ncbi.nlm.nih.gov/pubmed/?term=12649301;
https://www.ncbi.nlm.nih.gov/pubmed/?term=16115943
Pomalidomide is a derivative of thalidomide marketed by Celgene, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23940785
Curator's Comment: In vitro cell culture experiments were carried out to further investigate the impact of POM on the biology of macrophages. POM crosses the blood brain barrier with CNS penetration of ~ 39%.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: 7124.0 Gene Symbol: TNF Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=22966948 |
13.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | POMALYST Approved UseIndicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Launch Date2013 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75 ng/mL |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POMALIDOMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
860 ng × h/mL |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POMALIDOMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.5 h |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POMALIDOMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
POMALIDOMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
DLT: Diarrhea, Thrombocytopenia... Dose limiting toxicities: Diarrhea (grade 3, 3 patients) Sources: Thrombocytopenia (grade 3, 3 patients) Lung infection (grade 3, 3 patients) Neutropenia (grade 4, 3 patients) Lung infection (grade 3, 1 patient) Thrombocytopenia (grade 3, 1 patient) |
2.6 mg/m2 1 times / day steady, oral MTD Dose: 2.6 mg/m2, 1 times / day Route: oral Route: steady Dose: 2.6 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
DLT: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 4, 1 patient) Sources: |
10 mg 1 times / day steady, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, 56 years (range: 20–85 years) n = 2 Health Status: unhealthy Condition: advanced solid tumors Age Group: 56 years (range: 20–85 years) Sex: M+F Population Size: 2 Sources: |
DLT: Dyspnea, Neutropenia... Dose limiting toxicities: Dyspnea (grade 3, 2 patients) Sources: Neutropenia (grade 4, 1 patient) |
4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Disc. AE: Birth defects, Venous thromboembolism... Other AEs: Neutropenia, Anemia... AEs leading to discontinuation/dose reduction: Birth defects (grade 5) Other AEs:Venous thromboembolism (serious, 3%) Neutropenia (grade 3-4, 47%) Sources: Anemia (grade 3-4, 22%) Thrombocytopenia (grade 3-4, 22%) Dizziness (grade 3-4, 1%) |
4 mg 1 times / day steady, oral MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 14 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 14 Sources: |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 2 patients) Sources: |
2 mg 1 times / day steady, oral Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 6 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 6 Sources: |
DLT: Fatigue... Dose limiting toxicities: Fatigue (grade 3, 1 patient) Sources: |
3 mg 1 times / day steady, oral Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 8 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 8 Sources: |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 1 patient) Sources: |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 10 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 10 Sources: |
DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 3-4, 4 patients) Sources: |
50 mg single, oral Highest studied dose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy n = 30 Health Status: healthy Population Size: 30 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Lung infection | grade 3, 1 patient DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Thrombocytopenia | grade 3, 1 patient DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Diarrhea | grade 3, 3 patients DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Lung infection | grade 3, 3 patients DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Thrombocytopenia | grade 3, 3 patients DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Neutropenia | grade 4, 3 patients DLT |
3.4 mg/m2 1 times / day steady, oral Highest studied dose Dose: 3.4 mg/m2, 1 times / day Route: oral Route: steady Dose: 3.4 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Thrombocytopenia | grade 4, 1 patient DLT |
2.6 mg/m2 1 times / day steady, oral MTD Dose: 2.6 mg/m2, 1 times / day Route: oral Route: steady Dose: 2.6 mg/m2, 1 times / day Sources: |
unhealthy, 12.3 years (range: 5.8-20.8 years) n = 29 Health Status: unhealthy Condition: recurrent, progressive, or refractory CNS tumor Age Group: 12.3 years (range: 5.8-20.8 years) Sex: M+F Population Size: 29 Sources: |
Dyspnea | grade 3, 2 patients DLT |
10 mg 1 times / day steady, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, 56 years (range: 20–85 years) n = 2 Health Status: unhealthy Condition: advanced solid tumors Age Group: 56 years (range: 20–85 years) Sex: M+F Population Size: 2 Sources: |
Neutropenia | grade 4, 1 patient DLT |
10 mg 1 times / day steady, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, 56 years (range: 20–85 years) n = 2 Health Status: unhealthy Condition: advanced solid tumors Age Group: 56 years (range: 20–85 years) Sex: M+F Population Size: 2 Sources: |
Dizziness | grade 3-4, 1% | 4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Anemia | grade 3-4, 22% | 4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Thrombocytopenia | grade 3-4, 22% | 4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Neutropenia | grade 3-4, 47% | 4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Birth defects | grade 5 Disc. AE |
4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Venous thromboembolism | serious, 3% Disc. AE |
4 mg 1 times / day steady, oral Recommended|MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 61 years (range: 37 - 88 years) n = 107 Health Status: unhealthy Condition: relapsed multiple myeloma Age Group: 61 years (range: 37 - 88 years) Sex: M+F Population Size: 107 Sources: |
Neutropenia | grade 4, 2 patients DLT |
4 mg 1 times / day steady, oral MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 14 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 14 Sources: |
Fatigue | grade 3, 1 patient DLT |
2 mg 1 times / day steady, oral Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 6 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 6 Sources: |
Neutropenia | grade 4, 1 patient DLT |
3 mg 1 times / day steady, oral Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 8 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 8 Sources: |
Neutropenia | grade 3-4, 4 patients DLT |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, 64.7 years (range: 55-72 years) n = 10 Health Status: unhealthy Condition: relapsed and refractory multiple myeloma Age Group: 64.7 years (range: 55-72 years) Sex: M+F Population Size: 10 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | unknown Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000ClinPharmR.pdf#page=4 Page: 4.0 |
|||
major | unknown Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000ClinPharmR.pdf#page=4 Page: 4.0 |
|||
minor | ||||
minor | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000ClinPharmR.pdf#page=15 Page: 15.0 |
yes | |||
yes | unknown Comment: Clinical DDI studies to assess the influence of CYP3A4, CYP1A2 and P-gp inhibitors on pomalidomide exposure and any metabolites is planned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. | 2005 May 15 |
|
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. | 2005 Oct |
|
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. | 2013 Apr |
|
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. | 2014 Aug 7 |
Patents
Sample Use Guides
4 mg per day taken orally on Days 1-21 of repeated 28
day cycles until disease progression
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=19009291
When a PBMC population was maintained in IL-2 over a period of 7 days, the addition of pomalidomide 1 μM (IC50) in the incubation significantly decreased the proportion/number of Tregs in the population, compared with untreated controls.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:19 GMT 2023
by
admin
on
Fri Dec 15 15:29:19 GMT 2023
|
Record UNII |
D2UX06XLB5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL04AX06
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
FDA ORPHAN DRUG |
308610
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
FDA ORPHAN DRUG |
635818
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/10/759
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
FDA ORPHAN DRUG |
161402
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
FDA ORPHAN DRUG |
363212
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
NCI_THESAURUS |
C129820
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
NCI_THESAURUS |
C54677
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
WHO-ATC |
L04AX06
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
NDF-RT |
N0000184014
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000126117
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
7348
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
C467566
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
8222
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
D2UX06XLB5
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
DTXSID40893458
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
134780
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
DB08910
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
Pomalidomide
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
SUB33379
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
m8978
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
1369713
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
SS-115
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
POMALIDOMIDE
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
C72560
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
8873
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
4746
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
D2UX06XLB5
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL43452
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
72690
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | |||
|
POMALYST
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY | APPROVED MARCH 2015 | ||
|
19171-19-8
Created by
admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |
Pomalidomide is a racemic mixture of the S-enantiomer (CC-5083) and the R-enantiomer (CC-6016) which interconvert in plasma via both enzymatic and non-enzymatic pathways.
|
||
|
ENANTIOMER -> RACEMATE |
Pomalidomide is a racemic mixture of the S-enantiomer (CC-5083) and the R-enantiomer (CC-6016) which interconvert in plasma via both enzymatic and non-enzymatic pathways.
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
Dose-dependent interaction with the CRBN-DDB1 complex
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL; PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Vdss | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||